BioNTech, a German biotechnology company specializing in the development and manufacture of immunotherapies active in the treatment of serious diseases, is banking on Africa to boost its production. In this sense, it plans to open a factory in one of the following five countries: Morocco, Egypt, South Africa, Tunisia or Senegal.
The German biotech – which is behind the vaccine developed with Pﬁzer – has unveiled part of its expansion plan to create a large factory for the production of innovative drugs in Africa. According to its managing director, Ugur Sahin, the German ﬁrm plans to build a factory in Africa and develop a manufacturing network with local partners to transfer its technology based on messenger RNA – a genetic molecule – to a suffering continent of lack of access to vaccines and other life-saving treatments.
In his sights, five African countries that have a vaccine industry. These are Morocco, Egypt, South Africa, Tunisia and Senegal. The German ﬁrm intends to negotiate the possibilities of opening a factory in one of these countries.